Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DBVT NASDAQ:EOLS NASDAQ:KRRO NASDAQ:SCLX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDBVTDBV Technologies$16.95-0.3%$10.91$2.20▼$18.00$464.35M-0.45157,449 shs106,756 shsEOLSEvolus$6.40+1.6%$6.75$5.71▼$17.44$413.98M1.041.06 million shs532,798 shsKRROKorro Bio$42.15-13.3%$32.74$10.29▼$85.00$395.83M2.89287,631 shs337,615 shsSCLXScilex$12.78-4.0%$20.45$3.60▼$39.90$88.89M1.36312,187 shs200,547 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDBVTDBV Technologies0.00%+13.00%+76.75%+69.50%+370.83%EOLSEvolus0.00%+4.23%-0.31%-30.43%-63.32%KRROKorro Bio0.00%-1.91%+26.88%+208.34%-45.26%SCLXScilex0.00%-14.40%-50.19%+44.24%-58.03%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDBVTDBV Technologies$16.95-0.3%$10.91$2.20▼$18.00$464.35M-0.45157,449 shs106,756 shsEOLSEvolus$6.40+1.6%$6.75$5.71▼$17.44$413.98M1.041.06 million shs532,798 shsKRROKorro Bio$42.15-13.3%$32.74$10.29▼$85.00$395.83M2.89287,631 shs337,615 shsSCLXScilex$12.78-4.0%$20.45$3.60▼$39.90$88.89M1.36312,187 shs200,547 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDBVTDBV Technologies0.00%+13.00%+76.75%+69.50%+370.83%EOLSEvolus0.00%+4.23%-0.31%-30.43%-63.32%KRROKorro Bio0.00%-1.91%+26.88%+208.34%-45.26%SCLXScilex0.00%-14.40%-50.19%+44.24%-58.03%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDBVTDBV Technologies 2.43Hold$14.75-12.98% DownsideEOLSEvolus 2.40Hold$21.25232.03% UpsideKRROKorro Bio 3.00Buy$86.83106.01% UpsideSCLXScilex 2.00Hold$437.503,323.32% UpsideCurrent Analyst Ratings BreakdownLatest SCLX, DBVT, KRRO, and EOLS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/14/2025EOLSEvolusWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/14/2025KRROKorro BioWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025DBVTDBV TechnologiesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025SCLXScilexWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/29/2025DBVTDBV TechnologiesZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold9/27/2025DBVTDBV TechnologiesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025EOLSEvolusWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025KRROKorro BioWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025SCLXScilexWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/8/2025EOLSEvolusBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$18.008/13/2025KRROKorro BioChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$25.00(Data available from 10/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDBVTDBV TechnologiesN/AN/AN/AN/A$1.42 per shareN/AEOLSEvolus$277.94M1.49N/AN/A$0.09 per share71.11KRROKorro Bio$6.28M63.02N/AN/A$17.12 per share2.46SCLXScilex$56.59M1.57N/AN/A($27.68) per share-0.46Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDBVTDBV Technologies-$113.92M-$4.77N/AN/AN/A-3,220.49%-287.15%-138.83%11/5/2025 (Estimated)EOLSEvolus-$50.42M-$0.98N/AN/AN/A-22.31%-759.04%-24.63%11/5/2025 (Estimated)KRROKorro Bio-$83.58M-$9.75N/AN/AN/AN/A-61.51%-42.87%11/11/2025 (Estimated)SCLXScilex-$72.81M-$29.02N/AN/AN/A-179.12%N/A-109.95%11/12/2025 (Estimated)Latest SCLX, DBVT, KRRO, and EOLS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/12/2025N/ASCLXScilex-$0.41N/AN/AN/A$26.25 millionN/A11/11/2025Q3 2025KRROKorro Bio-$2.61N/AN/AN/A$0.41 millionN/A11/5/2025Q3 2025DBVTDBV Technologies-$1.45N/AN/AN/A$0.76 millionN/A11/5/2025Q3 2025EOLSEvolus-$0.14N/AN/AN/A$67.75 millionN/A8/13/2025Q2 2025SCLXScilex-$4.55-$7.42-$2.87-$7.42$26.25 million$9.90 million8/12/2025Q2 2025KRROKorro Bio-$2.54-$2.74-$0.20-$2.74$0.41 million$1.46 million7/29/2025Q2 2025DBVTDBV Technologies-$0.21-$1.55-$1.34-$1.55$0.64 million$1.74 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDBVTDBV TechnologiesN/AN/AN/AN/AN/AEOLSEvolusN/AN/AN/AN/AN/AKRROKorro BioN/AN/AN/AN/AN/ASCLXScilexN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDBVTDBV TechnologiesN/A2.452.45EOLSEvolusN/A2.271.86KRROKorro BioN/A5.985.98SCLXScilexN/A0.110.10Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDBVTDBV Technologies71.74%EOLSEvolus90.69%KRROKorro Bio13.18%SCLXScilex69.67%Insider OwnershipCompanyInsider OwnershipDBVTDBV Technologies1.44%EOLSEvolus5.90%KRROKorro Bio4.60%SCLXScilex7.94%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDBVTDBV Technologies8027.40 million27.00 millionOptionableEOLSEvolus17064.69 million60.87 millionOptionableKRROKorro Bio709.39 million8.96 millionNo DataSCLXScilex806.96 million6.40 millionNo DataSCLX, DBVT, KRRO, and EOLS HeadlinesRecent News About These CompaniesScilex (NASDAQ:SCLX) Given Sell (D-) Rating at Weiss RatingsOctober 9, 2025 | marketbeat.comDatavault AI: The New AI Contender Backed by Big Funding (SCLX)...October 1, 2025 | marketbeat.comScilex Holding Company Enters Warrant Exercise AgreementOctober 1, 2025 | tipranks.comDatavault AI (NASDAQ: DVLT) Closes Initial Tranche of $150M Bitcoin Investment from Scilex HoldingOctober 1, 2025 | financial-news.co.ukScilex Holding Company Completes Repurchase of 3.13 Million Warrants from Oramed Pharmaceuticals for $13 MillionOctober 1, 2025 | quiverquant.comQScilex Holding Company Announces the Completion of the First Tranche of the Oramed Pharmaceuticals, Inc. Warrant RepurchaseOctober 1, 2025 | globenewswire.comScilex Holding Company $SCLX Shares Bought by Goldman Sachs Group Inc.October 1, 2025 | marketbeat.comDatavault AI: Fresh Capital, Blue-Chip Partnership Back A Speculative BuySeptember 30, 2025 | seekingalpha.comScilex Enters Crypto Market with $200M Bitcoin DealSeptember 26, 2025 | tipranks.comScilex Holding Company Updates Board After Business MergerSeptember 26, 2025 | tipranks.comScilex Invests $150 Million in Datavault AISeptember 26, 2025 | tipranks.comDatavault AI Announces Closing of Initial Tranche Investment from Scilex Holding CompanySeptember 26, 2025 | businesswire.comScilex Holding Company Completes Initial Tranche of $150 Million Investment in Datavault AI Inc.September 26, 2025 | quiverquant.comQScilex Holding Company Announces Closing of Previously Announced Initial Tranche Investment in Datavault AISeptember 26, 2025 | globenewswire.comScilex to make $150M bitcoin investment in Datavault AISeptember 25, 2025 | msn.comScilex Holding Company Announces $150 Million Bitcoin Investment in Datavault AI Inc. to Accelerate Growth and InnovationSeptember 25, 2025 | quiverquant.comQScilex Holding Company Announces $150 Million Strategic Bitcoin Investment in Datavault AISeptember 25, 2025 | globenewswire.comScilex Announces Closing of Previously Announced Non-Dilutive Value Enhancing Transaction with an Institutional Investor for the Exchange of $200 Million of Common Stock of ...September 25, 2025 | finanznachrichten.deScilex Announces Closing of Previously Announced Non-Dilutive Value Enhancing Transaction with an Institutional Investor for the Exchange of $200 Million of Common Stock of Semnur Pharmaceuticals, Inc. Held by Scilex Holding Company for $200 Million in BitcoinSeptember 25, 2025 | globenewswire.comScilex enters MOU with Biconomy.com to collaborate on crypto strategySeptember 24, 2025 | msn.comScilex Holding Company Partners with Biconomy.com to Explore Cryptocurrency and Treasury Management StrategiesSeptember 24, 2025 | quiverquant.comQNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSCLX, DBVT, KRRO, and EOLS Company DescriptionsDBV Technologies NASDAQ:DBVT$16.95 -0.05 (-0.29%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$16.84 -0.11 (-0.64%) As of 10/17/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.Evolus NASDAQ:EOLS$6.40 +0.10 (+1.59%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$6.35 -0.05 (-0.78%) As of 10/17/2025 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.Korro Bio NASDAQ:KRRO$42.15 -6.45 (-13.27%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$42.06 -0.09 (-0.23%) As of 10/17/2025 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Korro Bio, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, OPERA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe alcohol-associated hepatitis, and other subsets of pain. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.Scilex NASDAQ:SCLX$12.78 -0.53 (-3.98%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$12.67 -0.11 (-0.86%) As of 10/17/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. The company is also developing three product candidates, including SP-102 (10 mg dexamethasone sodium phosphate viscous gel) (SEMDEXA), a novel viscous gel formulation of a used corticosteroid for epidural injections, which has completed a Phase 3 study to treat lumbosacral radicular pain or sciatica; SP-103 (lidocaine topical system) 5.4% (SP-103), a formulation of ZTlido for the treatment of chronic neck pain and low back pain (LBP) that has completed a Phase 2 trial; and SP-104 (4.5 mg low-dose naltrexone hydrochloride delayed-release capsules) (SP-104), a novel low-dose delayed-release naltrexone hydrochloride, which has completed Phase 1 trials for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Broadcom Inks OpenAI Deal: Why It's A Huge Win for AVGO Stock Institutions Are Fueling CrowdStrike’s Next Leg Higher This AI Chip Giant Could Be the Market’s Next Big Winner Microsoft & NVIDIA Unveil GB300 Supercomputer as AI Race Heats Up This Less-Hyped Tech Stock Could Be the Key to the Next AI Wave Archer Buys Rival's Patent Treasure Trove in Strategic Move Prologis Stock Surges: Why the Rally May Continue Intel's Turnaround Hits Hyperspeed With A New 52-Week High Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
